Drugs / BIOD-531
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02212951 | May → Jul 2014 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1/2 | NCT02324309 | May → Nov 2014 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02446028 | May 2015 → Feb 2016 | type 2 diabetes mellitus | Biodel | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIOD 531 | “BIOD 531 is a formulation of recombinant human insulin with a biphasic absorption profile characterized by rapid absorption (to prevent meal-time rises in blood glucose) and a...” NCT02446028 ↗ |
| Modality | Protein / enzyme biologic | “BIOD-531, a rapidly absorbed concentrated insulin” NCT02212951 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of 0.6 U/kg” NCT02212951 ↗ |